Nuclear Medicine

Molecular Imaging: Radiopharmaceuticals for PET and SPECT

Posted on August 13, 2013December 6, 2020 by admin

13
Aug

By

Shankar Vallabhajosula, Ph.D., Professor of Radiochemistry and Radiopharmacy in Radiology, Weill Cornell Medical College of Cornell University, Citigroup Biomedical Imaging Center (CBIC), New York, NY, USA

Radioisotope-based molecular imaging probes provide unprecedented insight into biochemistry and function involved in both normal and disease states of living systems, with unbiased in vivo measurement of regional radiotracer activities offering very high specificity and sensitivity. No other molecular imaging technology including functional magnetic resonance imaging (fMRI) can provide such high sensitivity and specificity at a tracer level. The applications of this technology can be very broad ranging from drug development, pharmacokinetics, clinical investigations, and finally to routine diagnostics in radiology. The design and the development of radiopharmaceuticals for molecular imaging studies using PET/MicroPET or SPECT/MicroSPECT are a unique challenge. This book is intended for a broad audience and written with the main purpose of educating the reader on various aspects including potential clinical utility, limitations of drug development, and regulatory compliance and approvals.

A comprehensive review of radioisotope-based molecular imaging probes (radiopharmaceuticals) for PET and SPECT
Covers basics of nuclear chemistry, radiochemistry and radiopharmacology
Discusses potential applications in drug development, translational medicine and clinical diagnostics
Presents a synthesis of radiopharmaceuticals, GMPs and regulatory issues
Written by an experienced radiochemist and scientist